Ablynx N.V.. (5/16/17). "Press Release: Ablynx to Present at Upcoming USA Investor Conferences". Ghent.

	Region	New York, NY
	Country	United States (USA)
	Organisation	Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)
	Group	Sanofi (Group) [since May 2011]
	Organisation 2	UBS (Group)
	Product	UBS Global Healthcare Conference
	Product 2	Jefferies 2017 Global Healthcare Conference New York
	Person	Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry)
	Person 2	Vanneste, Lies (Ablynx 201705 Director Invesor Relations)

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announces that it will participate in the following upcoming investor conferences taking place in New York City, USA:

> UBS Global Healthcare Conference: presentation is scheduled for Wednesday 24 May 2017 at 8.30 a.m. Eastern Standard Time (2.30 p.m. Central European Time), followed by a breakout session and one-on-one meetings with institutional investors

> Jefferies Healthcare Conference: presentation is scheduled for Tuesday 6 June 2017 at 11.30 a.m. Eastern Standard Time (5.30 p.m. Central European Time), followed by a breakout session and one-on-one meetings with institutional investors. The presentation will be webcast live and can be accessed on the day via this link.

> JMP Securities Life Sciences Conference: one-on-one meetings with institutional investors are scheduled for Tuesday 20 June 2017

The presentations will be given by Dr Edwin Moses, CEO of Ablynx and will be available on the Company’s website, under the News & Events section.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact:

Ablynx
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Lies Vanneste
Director IR
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
@AblynxABLX

Ablynx media/analyst relations:
FTI Consulting
Julia Phillips, Brett Pollard, Mo Noonan
t: +44 20 3727 1000
e: ablynx@fticonsulting.com

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Record changed: 2023-06-05